

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient Information

Patient's Name: _____

Insurance ID: _____ Date of Birth: _____ Height: _____ Weight: _____

Address: _____ Apartment #: _____

City: _____ State: _____ Zip Code: _____

Phone Number: _____ Alternate Phone: _____ Sex: Male Female

Provider Information

Provider's Name: _____ Provider ID Number: _____

Address: _____ City: _____ State: _____ Zip Code: _____

Suite Number: _____ Building Number: _____

Phone Number: _____ Fax number: _____

Provider's Specialty: _____

Medication Information

Medication: _____ Quantity: _____ ICD10 Code: _____

Directions: _____ Diagnosis: _____ Refills: _____

Physician Signature:** _____ Initial here if DAW: _____

*Physician Signature**:* By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.

Medication Instructions

Has the patient been instructed on how to **Self-Administer**? Yes No

Is this medication a **New Start**? Yes No

If continuation please provide the following: Initiation Date: / / Date of Last Dose: / /

Is there documentation of positive clinical response to current therapy? Yes No

****Please attach any pertinent clinical information that would pertain to support stated diagnosis. Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.**

Delivery Instructions

Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"

Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery

Ship to: Physician's Office Patient's Address Date medication is needed: / /

Medication Administered: Home Health Self-Administered LTC Physician's Office



Monoclonal Antibodies – Anti-IL, Anti-IgE - Pennsylvania

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Information

| | | |
|-------------|------------|------------|
| First Name: | Last Name: | Member ID: |
| Address: | | |
| City: | State: | ZIP Code: |
| Phone: | DOB: | Allergies: |

Primary Insurance Information:

Is the requested medication **New** or **Continuation of Therapy**? If continuation, list start date: _____

Is this patient currently hospitalized? **Yes** **No** If recently discharged, list discharge date: _____

Section B - Provider Information

| | | |
|-------------|------------|------------------------|
| First Name: | Last Name: | M.D./D.O. |
| Address: | City: | State: ZIP code: |
| Phone: | Fax: | NPI #: Specialty: |

Office Contact Name / Fax attention to:

Section C - Medical Information

| | |
|---|--------------|
| Medication: | Strength: |
| Directions for use: | Quantity: |
| Diagnosis (Please be specific & provide as much information as possible): | ICD-10 CODE: |

Is this member pregnant? **Yes** **No** If yes, what is this member's due date? _____

Section D – Previous Medication Trials

| Medications | Strength | Directions | Dates of Therapy | Reason for failure / discontinuation |
|-------------|----------|------------|------------------|--------------------------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs: Please refer to the patient's PDL at www.uhcprovider.com for a list of preferred alternatives

| | | |
|--------------------|-------------------|-------------|
| Member First name: | Member Last name: | Member DOB: |
|--------------------|-------------------|-------------|

Clinical and Drug Specific Information

ALL REQUESTS

| | |
|--|---|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have one of the following diagnoses? <i>(If yes, check which applies)</i> <input type="checkbox"/> Asthma <input type="checkbox"/> Chronic idiopathic urticaria |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Is the requested medication prescribed by or in consultation with an appropriate specialist (i.e., pulmonologist, allergist, immunologist, dermatologist, rheumatologist, etc.)? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Has the patient received appropriate vaccinations as recommended in the FDA-approved package labeling unless contraindicated? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Will the patient be evaluated, treated, and/or monitored for parasitic (helminth) infection before and/or during treatment with the prescribed monoclonal antibody (MAB) – anti-interleukin (IL), anti-immunoglobulin E (IgE) as recommended in FDA-approved package labeling? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Will the requested medication be used in combination with another MAB – anti-IL, anti-IgE? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have a documented history of therapeutic failure, intolerance, or contraindication of the preferred MAB – anti-IL, anti-IgE approved or medically accepted for the beneficiary’s indication? <i>(If yes, complete Section D above)</i> |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have a current history (within the past 90 days) of being prescribed the same non-preferred MAB – anti-IL, anti-IgE? |

ASTHMA

| | |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have an asthma severity that is consistent with the FDA-approved indication for the prescribed MAB – anti-IL, anti-IgE despite maximal therapeutic doses of or intolerance or contraindication to asthma controller medications based on current national treatment guidelines for the diagnosis and management of asthma? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Will the patient use the requested MAB – anti-IL, anti-IgE in addition to standard asthma controller medications as recommended by current national treatment guidelines for the diagnosis and management of asthma? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have asthma with an eosinophilic phenotype? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have one of the following? <i>(If yes, check which applies)</i> <input type="checkbox"/> Absolute blood eosinophil count greater than or equal to 150 cells/microliter <input type="checkbox"/> Absolute blood eosinophil count greater than or equal to 400 cells/microliter |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | For Xolair (omalizumab), does any of the following apply? <i>(If yes, check which applies)</i> <input type="checkbox"/> Has a diagnosis of allergen-induced asthma (allergic asthma confirmed by either a positive skin test or radioallergosorbent test) to an unavoidable perennial aeroallergen (e.g., pollen, mold, dust mite, etc.) <input type="checkbox"/> Has a serum total IgE measurement between 30 International Units/milliliter and 1300 International Units/milliliter |

CHRONIC IDIOPATHIC URTICARIA

| | |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have a documented history of urticaria for a period of at least 3 months? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient require steroids to control urticarial symptoms? |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have a documented history of therapeutic failure, contraindication, or intolerance to maximum tolerated doses of any of the following? <i>(If yes, check which applies and complete Section D above)</i> <input type="checkbox"/> Histamine 1 (H1) antihistamine <input type="checkbox"/> Histamine 2 (H2) antihistamine <input type="checkbox"/> Leukotriene modifier <input type="checkbox"/> Dapsone, sulfasalazine, or hydroxychloroquine |

CONTINUATION OF THERAPY – ASTHMA (cont’d on the next page)

| | |
|--|--|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Is the patient being monitored and treated, if applicable, for parasitic (helminth) infection as recommended in the Food and Drug Administration (FDA)-approved package labeling? |
|--|--|

Monoclonal Antibodies – Anti-IL, Anti-IgE - Pennsylvania

PRIOR AUTHORIZATION REQUEST FORM

| | | |
|--|---|--------------------|
| Member First name: | Member Last name: | Member DOB: |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have documented measurable evidence of improvement in the severity of the asthma condition? | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient continue to use the requested MAB – Anti-IL, Anti-IgE in addition to standard asthma controller medications as recommended by current national treatment guidelines for the diagnosis and management of asthma? | |
| CONTINUATION OF THERAPY - CHRONIC IDIOPATHIC URTICARIA | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Is the patient being monitored and treated, if applicable, for parasitic (helminth) infection as recommended in the Food and Drug Administration (FDA)-approved package labeling? | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Does the patient have documentation of any of the following? (If yes, check which applies) | |
| <input type="checkbox"/> Improvement of symptoms <input type="checkbox"/> Rationale for continued use | | |

Physician Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.